Loading...

Orbis Biosciences Named Finalist in the Fierce Innovation Awards

Orbis Biosciences Named Finalist in the Fierce Innovation Awards

LENEXA, KS – December 8, 2017 – Orbis Biosciences, Inc., is a finalist for the FierceBiotech and FiercePharma (Fierce) Innovation Awards. Orbis Biosciences’ submission in the Drug Delivery Technology category, “Optimum® Delivery Platform,” discusses Orbis’ ability to reduce the complexity of creating functional coatings, including enteric coatings. “The innovation in Orbis’ technology platforms changes how manufacturing is performed across pharma, and we are excited to be recognized for this innovation,” says Maria Flynn, CEO and President of Orbis Biosciences. Focus on innovation is reflected in the Fierce awards’ goal of recognizing companies with the most innovative technologies having the greatest potential to make an impact for biotech and pharma companies.

The Fierce Innovation Awards’ focus is on innovation that makes a positive, real-world impact on the biotech and pharma industries. Finalists were chosen based on their technical innovation and potential for cost savings. FiercePharma and FierceBiotech aim to analyze and provide the latest news on drugs, drug companies, and biotechnology companies. A complete listing of the finalists can be found here: https://questex-lifesciences2017.secure-platform.com/a/
 
About Orbis Biosciences – Orbis is a pharmaceutical manufacturing technology company focused on licensing its technology to pharmaceutical companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging Orbis’ novel technology platforms: Optimµm® precision encapsulation for oral delivery, StratµmTM precision encapsulation for injectable delivery, and the Unisun® platform for enabling sustained-release otic therapies. Providing industry innovation, the company offers cost-effective reformulation pathways to improve pharmaceutical products for improved health outcomes.
 
Media Contact: Brad Spitz (913-544-1199)
By | 2018-07-10T20:29:54+00:00 June 26th, 2018|Press Releases|0 Comments

About the Author:

Leave A Comment